Abstract
Retrospective analysis was performed to assess the survival-rates of children with non-Hodgkin lymphoma (NHL), treated according to the NHL-BFM (Berlin-Frankfurt-Münster)-90 and -95 protocols between 1990 and 2004 in Hungary, and to compare our data with the international results. Ninety-one patients had non-B-NHL, 108 B-NHL, and 31 ALCL. Complete remission rate was 89%, while 12% relapsed later. The 5-year-overall-survival was 78% and the event-free survival was 75%. These results are lower than those reported by the BFM study group, but comparable from other European centers. In the last 5 years, the results showed 10% improvement and death during induction was reduced from 10 to 3%.
(c) 2007 Wiley-Liss, Inc.
MeSH terms
-
Adolescent
-
Antibodies, Monoclonal / therapeutic use
-
Antibodies, Monoclonal, Murine-Derived
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Bone Marrow Transplantation
-
Child
-
Child, Preschool
-
Combined Modality Therapy
-
Disease-Free Survival
-
Europe / epidemiology
-
Female
-
Humans
-
Hungary / epidemiology
-
Immunotherapy
-
Infant
-
Kaplan-Meier Estimate
-
Lymphoma, Non-Hodgkin / drug therapy*
-
Lymphoma, Non-Hodgkin / epidemiology
-
Lymphoma, Non-Hodgkin / surgery
-
Male
-
Mortality / trends
-
Retrospective Studies
-
Rituximab
-
Survival Analysis
-
Treatment Outcome
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Murine-Derived
-
Rituximab